Literature DB >> 2983346

Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.

N C Dracopoli, A N Houghton, L J Old.   

Abstract

Loss of genetic material at certain chromosomal sites is implicated in the etiology of retinoblastoma and Wilms tumor. Whether specific chromosomal deletions are associated with other types of human cancer needs to be explored. We have examined 24 melanoma cell lines, derived from 21 patients with nonfamilial malignant melanoma, for evidence of somatically induced hemizygosity or homozygosity. Twelve DNA probes, recognizing single-copy restriction fragment length polymorphisms (RFLP) determined by loci on 11 different chromosomes, were used to screen autologous combinations of melanoma cells and either B cells or fibroblasts. Loss of heterozygosity in melanoma cells was identified at 27 of 100 informative loci. These losses occurred at loci on 8 different chromosomes, and the frequency of loss at individual loci varied between 8% and 67%. We conclude that somatic mutations resulting in homozygosity or hemizygosity are common in melanoma and evidently not restricted to specific chromosomes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983346      PMCID: PMC397284          DOI: 10.1073/pnas.82.5.1470

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Infectious murine leukemia virus from DNA of virus-negative AKR mouse embryo cells.

Authors:  D R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

3.  Clinical characteristics of the genetic variety of cutaneous melanoma in man.

Authors:  D E Anderson
Journal:  Cancer       Date:  1971-09       Impact factor: 6.860

4.  Isolation of a polymorphic DNA segment unique to human chromosome 7 by molecular cloning of hybrid cell DNA.

Authors:  P Humphries; D Barton; A M McKay; M M Humphries; B Carritt
Journal:  Mol Gen Genet       Date:  1983

5.  DNA polymorphic loci mapped to human chromosomes 3, 5, 9, 11, 17, 18, and 22.

Authors:  S L Naylor; A Y Sakaguchi; D Barker; R White; T B Shows
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus.

Authors:  M H Greene; L R Goldin; W H Clark; E Lovrien; K H Kraemer; M A Tucker; D E Elder; M C Fraser; S Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Loss of heterozygosity in cultured human tumor cell lines.

Authors:  N C Dracopoli; J Fogh
Journal:  J Natl Cancer Inst       Date:  1983-01       Impact factor: 13.506

8.  Polymorphic human somatostatin gene is located on chromosome 3.

Authors:  S L Naylor; A Y Sakaguchi; L P Shen; G I Bell; W J Rutter; T B Shows
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

9.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

10.  Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.

Authors:  A P Albino; K O Lloyd; A N Houghton; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more
  21 in total

1.  The anonymous polymorphic DNA clone D1S1, previously mapped to human chromosome 1p36 by in situ hybridization, is from chromosome 3 and is duplicated on chromosome 1.

Authors:  M E Goode; P vanTuinen; D H Ledbetter; S P Daiger
Journal:  Am J Hum Genet       Date:  1986-04       Impact factor: 11.025

2.  Levels of fos, ets2, and myb proto-oncogene RNAs correlate with segregation of chromosome 11 of normal cells and with suppression of tumorigenicity in human cell hybrids.

Authors:  B M O'Hara; H P Klinger; T Curran; Y D Zhang; D G Blair
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

3.  High resolution gene mapping of the human alpha globin locus.

Authors:  R D Nicholls; J A Jonasson; J O McGee; S Patil; V V Ionasescu; D J Weatherall; D R Higgs
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

4.  Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression.

Authors:  N C Dracopoli; P Harnett; S J Bale; B Z Stanger; M A Tucker; D E Housman; R F Kefford
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

5.  Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13.

Authors:  C Lundberg; L Skoog; W K Cavenee; M Nordenskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 6.  Cancer genes generated by rare chromosomal rearrangements rather than activation of oncogenes.

Authors:  P H Duesberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

7.  Loss of heterozygosity in hypotriploid cell cultures from testicular tumours.

Authors:  J M Parrington; L F West; S Povey
Journal:  Hum Genet       Date:  1987-11       Impact factor: 4.132

8.  Harvey ras genes transform without mutant codons, apparently activated by truncation of a 5' exon (exon -1).

Authors:  K Cichutek; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 9.  Antigens of melanocytes and melanoma.

Authors:  S A Lynch; B N Bouchard; S Vijayasaradhi; H Yuasa; A N Houghton
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 10.  Cytogenetics of human malignant melanoma.

Authors:  J M Trent
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.